A new report, The Pharmaceutical Cannabis Report: 3rd Edition, provides an in-depth global insight into the growing field of pharmaceutical cannabis. It presents a comprehensive analysis of the contemporary landscape of cannabis and cannabinoids in pharmaceutical medicine.
The report takes a deep dive into trials, patents and innovation and serves as a guide for business entrepreneurs and managers, giving them a strategic edge in a rapidly evolving industry. Global sales within this sector are expected to increase from $1,11 billion in 2023 to $1,37 billion in 2027.
Cannabis medicine
Epidiolex, known as Epidyolex in Europe, is expected to have an estimated market share of approximately 2023% by 76. However, the market is not limited to one player. Other drugs such as dronabinol and Sativex also have significant market positions, with dronabinol alone generating an estimated annual turnover of approximately €160 million.
The report also sheds light on the growing interest in the medical applications of cannabinoids, with Jazz Pharmaceuticals emerging as a patent giant in this field. Notably, despite the numerous cannabinoids available, CBD and THC remain at the forefront of patent activity, underscoring their historical and ongoing significance in the industry.
The report provides a clear overview of the costs associated with each phase of clinical trials. Because even the most conservative estimates assume a price tag of $20 million to bring a drug to market, this information is critical to strategic planning and investment decisions.
Furthermore, the report highlights the geographic concentration of pharmaceutical sales cannabis, identifying North America and Europe as the dominant regions. Within these areas, sales patterns show a focus on key markets, giving companies insight into potential target regions.
Source: finance.yahoo.com (EN)
